Educational Content Only: Not medical advice. Always consult a qualified healthcare provider before using any compounds. Many peptides are research chemicals not approved by the FDA.

hormonesFDA Approved

PT-141

Also known as: Bremelanotide, Vyleesi

The desire peptide — FDA-approved for female sexual dysfunction

Method

injection

Level

intermediate

Risk

high

Status

FDA Approved

Quick Summary

The desire peptide — FDA-approved for female sexual dysfunction

Also called: Bremelanotide, Vyleesi

What is PT-141?

PT-141 (Bremelanotide) is a synthetic melanocortin receptor agonist that was originally developed as a sunless tanning agent (Melanotan II) before its sexual effects were discovered. It is the first and only FDA-approved non-hormonal treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women (as Vyleesi). Unlike PDE5 inhibitors (Viagra, Cialis), PT-141 works centrally in the brain rather than through vascular mechanisms.

How It's Made

PT-141 is a cyclic heptapeptide analog of alpha-melanocyte stimulating hormone (alpha-MSH). It is produced via solid-phase peptide synthesis. The FDA-approved version (Vyleesi) is available as a subcutaneous auto-injector.

Potential Benefits

Increased sexual desire in both men and women
Enhanced arousal
Improved erectile function (men)
FDA-approved for female HSDD
Works when other treatments fail
Centrally acting (brain-based)

Who Uses This?

Common goals and use cases for PT-141:

Female hypoactive sexual desire disorder (HSDD)Male erectile dysfunction (off-label)Low libido in both sexesSexual dysfunction unresponsive to other treatments

Where to Buy PT-141

Affiliate links — use code for discount. Always consult a healthcare provider before use.

Want a personalized protocol?

Take our AI-powered quiz to get a peptide protocol tailored to your specific goals and health profile.